News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
4,585 Results
Type
Article (436)
Company Profile (2)
Press Release (4147)
Section
Business (1783)
Career Advice (8)
Deals (251)
Drug Delivery (4)
Drug Development (818)
FDA (140)
Job Trends (192)
News (2790)
Policy (268)
Tag
Academia (14)
Alliances (459)
Alzheimer's disease (1)
Antibody-drug conjugate (ADC) (23)
Approvals (144)
Artificial intelligence (8)
ASCO (5)
Autoimmune disease (3)
Bankruptcy (6)
Best Places to Work (164)
BIO (2)
BioSpace Insights (4)
Biotechnology (2)
Bladder cancer (24)
Brain cancer (1)
Breast cancer (1)
Cancer (82)
Career advice (7)
Career pathing (4)
CAR-T (4)
Cell therapy (18)
Clinical research (757)
Collaboration (24)
COVID-19 (5)
CRISPR (1)
C-suite (21)
Cystic fibrosis (1)
Data (59)
Dermatology (3)
Diagnostics (6)
Drug discovery (6)
Drug pricing (7)
Earnings (551)
Events (656)
Executive appointments (13)
FDA (169)
Frontotemporal dementia (2)
Funding (19)
Gene editing (3)
Generative AI (1)
Gene therapy (15)
GLP-1 (6)
Government (34)
Guidances (6)
Healthcare (33)
Immuno-oncology (1)
Indications (1)
Infectious disease (5)
Inflation Reduction Act (3)
Intellectual property (2)
IPO (93)
IRA (4)
Job creations (29)
Job search strategy (3)
JPM (1)
Kidney cancer (2)
Labor market (4)
Layoffs (16)
Leadership (1)
Legal (41)
Lung cancer (5)
Machine learning (1)
Manufacturing (4)
Medical device (2)
Medtech (2)
Mergers & acquisitions (161)
Metabolic disorders (1)
mRNA (2)
Multiple sclerosis (1)
Neurodegenerative disease (1)
Neuroscience (6)
NextGen: Class of 2026 (29)
Non-profit (27)
Opinion (5)
Pancreatic cancer (2)
Partnered (1)
Patents (1)
Patient recruitment (3)
People (590)
Phase 1 (205)
Phase 2 (271)
Phase 3 (361)
Pipeline (92)
Policy (8)
Postmarket research (18)
Preclinical (50)
Prostate cancer (18)
Radiopharmaceuticals (2)
Rare diseases (9)
Real estate (21)
Regulatory (237)
Reports (1)
Research institute (4)
Rett syndrome (2)
Series A (3)
Series B (2)
Special edition (1)
Spinal muscular atrophy (7)
Startups (47)
Stomach cancer (2)
The Weekly (2)
Vaccines (2)
Venture capital (4)
Weight loss (1)
Women's health (5)
Date
Today (1)
Last 7 days (2)
Last 30 days (16)
Last 365 days (168)
2026 (114)
2025 (157)
2024 (254)
2023 (353)
2022 (409)
2021 (395)
2020 (404)
2019 (288)
2018 (219)
2017 (212)
2016 (254)
2015 (222)
2014 (165)
2013 (149)
2012 (168)
2011 (202)
2010 (180)
Location
Africa (2)
Arizona (1)
Asia (629)
Australia (14)
California (128)
Canada (15)
China (7)
Europe (458)
Florida (1)
Georgia (3)
Illinois (23)
India (1)
Indiana (2)
Japan (46)
Maryland (2)
Massachusetts (62)
Michigan (1)
New Jersey (25)
New York (35)
Northern California (93)
Ohio (1)
Pennsylvania (6)
South America (5)
Southern California (30)
Tennessee (1)
Texas (3)
United States (294)
Washington D.C. (2)
Washington State (9)
4,585 Results for "astellas".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Bankruptcy
Lilly, Astellas circle Sangamo assets as biotech files for bankruptcy
As Sangamo runs out of cash, Eli Lilly and Astellas have emerged as stalking horse bidders for key assets, including a Fabry gene therapy currently being submitted for potential FDA approval.
June 23, 2026
·
3 min read
·
Gabrielle Masson
Layoffs
50 employees impacted as Astellas closes Universal Cells’ Seattle office
By closing the Universal Cells Seattle location, Astellas is reportedly consolidating cell therapy, gene therapy and oncology research at its South San Francisco, California, and Westborough, Massachusetts, sites.
April 14, 2026
·
2 min read
·
Angela Gabriel
Deals
Astellas Divorces CytomX Despite Positive Phase 1 Data for Antibody Platform
Astellas Pharma and CytomX Therapeutics first partnered up in March 2020. For $80 million upfront, the Japanese pharma gained access to the biotech’s Probody platform to generate masked antibody therapies for cancer.
March 17, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Sangamo Therapeutics Enters Into Asset Sale Agreements with Lilly and Astellas
June 23, 2026
·
7 min read
Press Releases
Astellas to Spotlight New Research for Geographic Atrophy at ASRS 2026 Annual Meeting
July 9, 2026
·
9 min read
Press Releases
Astellas Doses First Patient in Phase 3 Study of ASP2138 in CLDN18.2-postive and HER2-negative locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma
August 25, 2026
·
6 min read
Women’s health
AbCellera’s menopause medicine ‘sets new efficacy bar’ for hot flashes
AbCellera Biologics’ reduction in hot flashes sets it apart from currently commercial oral drugs, including Astellas’ Veozah and Bayer’s Lynkuet, according to BMO Capital Markets.
August 11, 2026
·
1 min read
·
Tristan Manalac
Press Releases
Astellas to Highlight New Findings for Geographic Atrophy at ARVO 2026 Annual Meeting
April 30, 2026
·
9 min read
Bankruptcy
Bankrupt Sangamo offloads assets to Lilly, PTC in $161M sale
PTC Therapeutics emerged as the winning bidder over Astellas for Sangamo Therapeutics’ Fabry disease gene therapy, while Eli Lilly is purchasing the biotech’s prion disease program and several platforms.
August 13, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Astellas Announces Five-Year Corporate Strategic Plan to Deliver Greater VALUE Faster for Patients and Position Itself as a Sustainable Growth Company
May 26, 2026
·
5 min read
1 of 459
Next
